: Acute tension and anxiety states. Agitation, insomnia, anxiety and age related depressive reactions.
Functional disturbance in the cardiovascular respiratory system: pseudoangina pectoris, precordial anxiety, tachycardia, emotiogenic hypertension, dyspnea and hyperventilation.
In the gastrointestinal system: Irritable bowel syndrome, epigastric pain, spasm, bloting diarrhoea, etc.
In the genitourinary system: Irritable bladder and dysmenorrhea.
Psychosomatic disorders: psychogenic headache, psychogenic dermatosis, asthma, gastric and duodenal ulcer, ulcerative colitis. Emotional reactions to chronic organic diseases.
Bromazepam binds to the GABA receptor GABAA
, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.
Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Use in adult
: The optimum dosage and frequency of administration of Bromazepam should be based on the individual patient, the severity of symptoms and previous psychotropic drug history. The usual dosage in general practice is from 3 mg to 18 mg daily in divided doses. In exceptional circumstances, in hospitalized patients, up to the maximum daily dosage of 60 mg, in divided doses, may be given.
Use in elderly: Elderly patients are more sensitive to the actions of Bromazepam. Doses should
not exceed half of those normally recommended
Use in children: Bromazepam is not recommended for paediatric use.
Bromazepam tablets are for oral administration
Phenothiazines, barbiturates, MAO inhibitors and psychoactive drugs may potentiate the action of Bromazepam and should not be given concurrently.
Patients with known hypersensitivity to benzodiazepines; acute pulmonary insufciency; respiratory depression phobic or obsessional states; chronic psychosis.
Common side effects include drowsiness, sedation, unsteadiness and ataxia; these are dose-related and may persist in the following day, even after a single dose. Drowsiness may be a particular problem when Bromazepam is used in higher dosage in some patients. Other side effects are rare and include headache, vertigo, hypotension, gastro-intestinal upsets skin rashes, visual disturbance & change in libido.
Use of benzodiazepines should be avoided during pregnancy, fetus may be affected. Bromazepam is secreted through human milk. So nursing mothers should not use this drug.
In patients with chronic pulmonary insufciency and in patients with chronic renal or hepatic disease, dosage may need to be reduced. If Bromazepam is combined with centrally acting drugs such as alcohol, neuroleptics, tranquilisers, antidepressants, antidepressants, hypnotics, analgesics and anesthetics, the sedative effects are likely to be intensified. The elderly require special supervision. Patients should be advised that, like all medicaments of this type, Bromazepam may modify patients’ performance at skilled tasks (driving, operating machine, etc.)
Signs may include drowsiness, ataxia and dysarthria, with coma in severe cases
Store in a cool dry place protected from light. Keep out of reach of children.